iPLATO helps NHS tackle £930m non-adherence cost
November 23, 2023
A Year to Remember: Reflecting on 2024 at iPLATO
By Tobias Alpsten, CEO and Founder of iPLATO
As 2024 comes to a close, I’ve been reflecting on what has been an extraordinary year for iPLATO. It’s been a year of milestones, growth, and partnerships that have taken us closer to our mission of improving healthcare access and outcomes for millions across the UK. This journey has been filled with proud moments, and I’m excited to share some of them with you.
The most significant step we’ve taken this year was joining forces with eConsult. In October this year, Huma acquired eConsult, a market leader within the digital triage and online consultation space in the UK.Together, we’ve combined iPLATO’s patient communication platform and eConsult’s online triage expertise to create a stronger, more integrated solution for healthcare providers.
What makes this so exciting is the potential we now have to serve over 50 million patients across the UK. We offered every iPLATO GP practice in England access to the iPLATO Toolbar for free, streamlining their patient communications and making it easier to provide timely care. At the same time, eConsult users are benefiting from tools like Selfbook, Connect, Patient Questionnaires and more! iPLATO users can now access eConsult’s structured online consultations.
This merger isn’t just about technology; it’s about the people. By bringing together our expertise, we’re making it easier for practices to offer high-quality care in a way that is accessible, efficient, and cost-effective.
Another highlight of 2024 has been the recognition we’ve received for our work. Winning the Best Virtual Care Project at the HTN Now Awards alongside Huma was a proud moment. The award was for our GDm-Health solution, which helps pregnant women with gestational diabetes manage their condition and enables clinicians to monitor them remotely. It’s a fantastic example of how digital tools can transform healthcare for both patients and providers.
We were also thrilled to be finalists in the British Data Awards, recognised for our efforts in tackling health inequalities. By analysing NHS data and deprivation indices, we’ve helped identify gaps in care and supported better resource allocation. This work is about making sure every patient gets the care they need, regardless of where they live or their circumstances.
We’ve also made great strides in building partnerships that bring tangible benefits to patients and practices. One of the most exciting moments was securing our contract with Wales, where we’ll be providing patient communications for all GP practices. This means practices across the country will have access to tools like the iPLATO Toolbar, enabling them to save time, improve communication, and focus on patient care.
Another important partnership was with Greater Manchester Cancer Alliance to promote the Targeted Lung Health Check programme. By using our Population Health service, we’re encouraging more people to participate in life-saving lung cancer screenings. It’s initiatives like this that remind me why we do what we do—to make a real difference in people’s lives.
We’ve also continued to support regions like Kent and Medway, Lancashire and South Cumbria, and Cambridge and Peterborough with tailored solutions that improve efficiency and free up valuable resources for frontline care.
Three practices in North Central London have reached a remarkable milestone, using our platform for an incredible 20 years! Clerkenwell Medical Practice, City Road Medical Centre, and The Goodinge Group Practice all onboarded in August 2004 and remain valued users of the platform to this day. We extend our gratitude to these practices for their ongoing support and trust in our digital solutions over the years. Here’s to continuing our partnership and driving even more innovation in healthcare together!
Our Population Health service is making strides in public health programmes, our most notable being BEST4 bowel cancer screening. iPLATO plays a pivotal role in partnering with the NHS to drive earlier identification of bowel cancer through innovative digital solutions. Recognising that bowel cancer accounts for 11% of all new cancer cases in the UK, iPLATO focuses on increasing screening uptake among underserved populations, breaking down barriers such as language, stigma, and socio-economic challenges. By delivering targeted SMS reminder programmes and leveraging Digital Patient Questionnaires — achieving completion rates of up to 42% — iPLATO has successfully increased bowel cancer screening uptake by 16%. These efforts help normalise screening within communities, promote education, and support earlier detection at stages 1-2, improving health outcomes while reducing treatment costs.
This year, we celebrated reaching three million users on the myGP app—a milestone that reflects how far we’ve come in empowering people to manage their health. Our app has become a vital tool for booking appointments, managing repeat prescriptions, and even checking blood pressure and skin health from the comfort of home.
In 2024 alone, myGP users booked over 1.1 million appointments and placed more than 12 million repeat prescription orders. We’ve also helped practices reclaim thousands of hours by managing cancellations more efficiently, freeing up time for patients who need it most.
Together with our pharmacy partners – LloydsDirect, Pharmacy2U, PillTime and Phlo – we simplified access to prescription medication through digital first. We also added tools to improve adherence and persistence to prescribed medication.
iPLATO’s partnership with Healthera’s national pharmacy network to enhance the myGP app with advanced Click-and-Collect prescription services and access to bookable pharmacy services, including flu and COVID-19 vaccinations and treatment for common conditions has been hugely successful. Through this partnership, myGP users can now seamlessly book vaccinations and manage prescriptions across over 1,500 local pharmacies in Healthera’s growing network. This integration not only simplifies access to essential healthcare services but also strengthens patient engagement with their local community pharmacies.
With over 30 million people eligible for free flu vaccines and NHS initiatives like Pharmacy First expanding access to care for seven common conditions, iPLATO and Healthera’s collaboration empowers patients to prioritise their health with ease.
Our innovations, like the Autoderm skin checker and Lifelight’s blood pressure checker, are helping people take control of their health in ways that are simple, effective, and accessible. It’s a privilege to see these tools making such a positive impact.
As we head into 2025, I’m more optimistic than ever about what we can achieve. Thank you to everyone who has been part of this journey—our partners, our team, and the millions of patients who trust us to help them manage their health.
Here’s to 2025!
Tobias
© 2026 iPLATO. All rights reserved
iPLATO helps NHS tackle £930m non-adherence cost
November 23, 2023
A Year to Remember: Reflecting on 2024 at iPLATO
By Tobias Alpsten, CEO and Founder of iPLATO
As 2024 comes to a close, I’ve been reflecting on what has been an extraordinary year for iPLATO. It’s been a year of milestones, growth, and partnerships that have taken us closer to our mission of improving healthcare access and outcomes for millions across the UK. This journey has been filled with proud moments, and I’m excited to share some of them with you.
The most significant step we’ve taken this year was joining forces with eConsult. In October this year, Huma acquired eConsult, a market leader within the digital triage and online consultation space in the UK.Together, we’ve combined iPLATO’s patient communication platform and eConsult’s online triage expertise to create a stronger, more integrated solution for healthcare providers.
What makes this so exciting is the potential we now have to serve over 50 million patients across the UK. We offered every iPLATO GP practice in England access to the iPLATO Toolbar for free, streamlining their patient communications and making it easier to provide timely care. At the same time, eConsult users are benefiting from tools like Selfbook, Connect, Patient Questionnaires and more! iPLATO users can now access eConsult’s structured online consultations.
This merger isn’t just about technology; it’s about the people. By bringing together our expertise, we’re making it easier for practices to offer high-quality care in a way that is accessible, efficient, and cost-effective.
Another highlight of 2024 has been the recognition we’ve received for our work. Winning the Best Virtual Care Project at the HTN Now Awards alongside Huma was a proud moment. The award was for our GDm-Health solution, which helps pregnant women with gestational diabetes manage their condition and enables clinicians to monitor them remotely. It’s a fantastic example of how digital tools can transform healthcare for both patients and providers.
We were also thrilled to be finalists in the British Data Awards, recognised for our efforts in tackling health inequalities. By analysing NHS data and deprivation indices, we’ve helped identify gaps in care and supported better resource allocation. This work is about making sure every patient gets the care they need, regardless of where they live or their circumstances.
We’ve also made great strides in building partnerships that bring tangible benefits to patients and practices. One of the most exciting moments was securing our contract with Wales, where we’ll be providing patient communications for all GP practices. This means practices across the country will have access to tools like the iPLATO Toolbar, enabling them to save time, improve communication, and focus on patient care.
Another important partnership was with Greater Manchester Cancer Alliance to promote the Targeted Lung Health Check programme. By using our Population Health service, we’re encouraging more people to participate in life-saving lung cancer screenings. It’s initiatives like this that remind me why we do what we do—to make a real difference in people’s lives.
We’ve also continued to support regions like Kent and Medway, Lancashire and South Cumbria, and Cambridge and Peterborough with tailored solutions that improve efficiency and free up valuable resources for frontline care.
Three practices in North Central London have reached a remarkable milestone, using our platform for an incredible 20 years! Clerkenwell Medical Practice, City Road Medical Centre, and The Goodinge Group Practice all onboarded in August 2004 and remain valued users of the platform to this day. We extend our gratitude to these practices for their ongoing support and trust in our digital solutions over the years. Here’s to continuing our partnership and driving even more innovation in healthcare together!
Our Population Health service is making strides in public health programmes, our most notable being BEST4 bowel cancer screening. iPLATO plays a pivotal role in partnering with the NHS to drive earlier identification of bowel cancer through innovative digital solutions. Recognising that bowel cancer accounts for 11% of all new cancer cases in the UK, iPLATO focuses on increasing screening uptake among underserved populations, breaking down barriers such as language, stigma, and socio-economic challenges. By delivering targeted SMS reminder programmes and leveraging Digital Patient Questionnaires — achieving completion rates of up to 42% — iPLATO has successfully increased bowel cancer screening uptake by 16%. These efforts help normalise screening within communities, promote education, and support earlier detection at stages 1-2, improving health outcomes while reducing treatment costs.
This year, we celebrated reaching three million users on the myGP app—a milestone that reflects how far we’ve come in empowering people to manage their health. Our app has become a vital tool for booking appointments, managing repeat prescriptions, and even checking blood pressure and skin health from the comfort of home.
In 2024 alone, myGP users booked over 1.1 million appointments and placed more than 12 million repeat prescription orders. We’ve also helped practices reclaim thousands of hours by managing cancellations more efficiently, freeing up time for patients who need it most.
Together with our pharmacy partners – LloydsDirect, Pharmacy2U, PillTime and Phlo – we simplified access to prescription medication through digital first. We also added tools to improve adherence and persistence to prescribed medication.
iPLATO’s partnership with Healthera’s national pharmacy network to enhance the myGP app with advanced Click-and-Collect prescription services and access to bookable pharmacy services, including flu and COVID-19 vaccinations and treatment for common conditions has been hugely successful. Through this partnership, myGP users can now seamlessly book vaccinations and manage prescriptions across over 1,500 local pharmacies in Healthera’s growing network. This integration not only simplifies access to essential healthcare services but also strengthens patient engagement with their local community pharmacies.
With over 30 million people eligible for free flu vaccines and NHS initiatives like Pharmacy First expanding access to care for seven common conditions, iPLATO and Healthera’s collaboration empowers patients to prioritise their health with ease.
Our innovations, like the Autoderm skin checker and Lifelight’s blood pressure checker, are helping people take control of their health in ways that are simple, effective, and accessible. It’s a privilege to see these tools making such a positive impact.
As we head into 2025, I’m more optimistic than ever about what we can achieve. Thank you to everyone who has been part of this journey—our partners, our team, and the millions of patients who trust us to help them manage their health.
Here’s to 2025!
Tobias
© 2026 iPLATO. All rights reserved

iPLATO helps NHS tackle £930m non-adherence cost
November 23, 2023
The myGP app from iPLATO – a Huma company – has just launched a new tool giving users support to improve their adherence to their long-term condition medication.
It is estimated that between 30 – 50% of medicines prescribed for long‑term conditions are not taken as recommended. myGP app’s new medication adherence feature lets users proactively take control of their medicine intake. The flexible in-app reminders support better control and self-management with adherence tracking.
It starts with improving access
A good place to start tackling non-adherence to improve people’s accessibility to their medication. According to The Health Foundation, women in the least deprived areas in England live a further 19.7 years in good health than those in the most deprived. For men, the difference is 18.4 years.
Today, over 100,000 myGP app users access their repeat medications through their nominated pharmacy partner. Choice is crucial to ensuring adequate access. Free home delivery and high-street click-and-collect options are available.
For those navigating physical challenges travelling to their pharmacy such as patients struggling with mobility issues or carers with little time to spare, access can be the first hurdle to maintaining good adherence. The task of taking multiple medications, as prescribed with differing doses and frequency can be the second.
The personal cost
Adherence challenges can have detrimental effects on the patient’s health, in more ways than one. Dr Harriet Leyland, Clinical Advisor at myGP comments, “medication adherence is crucial for managing ill-health. People living with chronic illness are particularly susceptible to poor adherence due to the number of medications they may have to take each day.”
If a medicine is not taken as prescribed, it will have limited effectiveness and can cause mental stress for the patient too. To help, people on the myGP app taking 3 or more medications can benefit from grouped and labelled medication deliveries provided by PillTime. It bundles multiple medicines into sachets with consumption day and time clearly labelled, with convenient at-home delivery.
The economic impact
The associated cost of non-adherence to five key conditions (asthma, type 2 diabetes, high cholesterol/coronary heart disease, hypertension, and schizophrenia) is estimated at over £930 million. If adherence were to be improved, it could result in annual savings of £500 million. Broken down, this cost to the NHS is a result of wasted medicines and the increased costs of treating worsening patient health.
Dr Harriet Leyland, continues, “myGP’s medicine reminder and tracking features supports patients to take their medicines, improving their adherence, supporting the reduction of medicine wastage whilst delivering better health outcomes.”
A wider lens
Across the EU, the impact of poor medicine compliance is said to contribute to almost 200,000 deaths a year. As we turn to technology to support and help minimise this gap, it is optimistic to see many companies innovating in the space, helping people to live healthier and longer lives.
Having recently received the EU MDR Class IIb certification, Huma’s remote patient monitoring app supports higher-risk patients managing long-term chronic diseases, with more challenging medication regimes to remain observant. Communication is possible between clinician and patient with alerts, notifications, and self-learning modules.
© 2026 iPLATO. All rights reserved